What GLP-1 supplier quality has to prove
Start with the market picture, briefly, because it explains why GLP-1 peptide supplier quality risk is not where most buyers assume it is.
The acute shortage is over. The FDA confirmed the tirzepatide shortage resolved in December 2024 and semaglutide in February 2025, and enforcement discretion for compounding those molecules wound down through early 2025. What did not resolve is capacity pressure. Industry analysis published in 2026 puts North American GLP-1 peptide API lines at roughly 90–95% utilization, with booking horizons of 12 to 18 months and longer waits for new entrants. Drug Discovery News reported in 2026 that although the systemic shortage had ended, the chain remained structurally tight, with intermittent backorders and demand well above historical norms.
The more useful observation is where the constraint moved. Synthesis capacity is no longer the only limiting step. Reverse-phase HPLC purification, resin and solvent supply, sterile fill-finish, and device assembly now carry much of the load, a shift in the bottleneck that 2026 capacity analysis attributes largely to resin supply and solvent-handling infrastructure rather than reactor time. Purification is exactly where impurity control is won or lost, uas txhais tau tias kev pheej hmoo zoo hauv kev muab GLP-1 niaj hnub no ze rau daim ntawv pov thawj dua li rau lub reactor.
Qhov ntawd ua rau muaj kev thov uas tag nrho cov khoom no nyob ntawm: kev lag luam ntau rau GLP-1 khoom tsis yog pov thawj ntawm kev lag luam ntau rau muaj txuj ci GLP-1 khoom. Kev muaj ntau yam tsis qhia txog seb cov khoom nyob pem koj puas tau txheeb xyuas kom raug, seb nws hom ntsev puas tau tswj, lossis seb qhov khoom koj tau txais puas zoo li qhov khoom uas tau kuaj.
Start with the tier your work actually requires
Qhov yuam kev tshaj plaws yog siv ib qho qauv nruab nrab thoob plaws txhua qhov kev siv. Ib qho kev tshuaj xyuas tshawb nrhiav thiab ib qho kev tshawb fawb IND tsis tas yuav muaj tib pob, and holding screening material to a development-grade specification wastes budget while holding in vivo material to a screening-grade one wastes a study.
| Use tier | Minimum package | Stronger expectation | Hard gate |
|---|---|---|---|
| Exploratory screening | HPLC purity ≥95%, MS identity | ≥98% with a disclosed chromatogram and method | Identity confirmed by MS, not calculated |
| Quantitative biochemical assay | ≥98% HPLC, lot-specific certificate, MS identity | ≥99%, plus counterion and residual-solvent data | Purity measured, not stated as a threshold |
| Cell culture and organoid work | Above, plus endotoxin by LAL | Low-endotoxin specification with units stated, plus an impurity profile | Endotoxin result reported in EU/mg |
| In vivo animal studies | Above, plus sterility where the route requires it | Full traceability, counterion and TFA data, residual solvents, lot history | Sterility tied to a recognized method |
| Kev tsim kho tswj hwm | Txoj kev tau lees paub, kev txheeb xyuas orthogonal, cov ntaub ntawv ruaj khov | Ib pob CMC-style tag nrho nrog kev tso tawm thiab txoj kev ruaj khov | Deviation and change-control records available |
Tiering is not a shortcut to lower quality. It is a way to know which attributes are pass/fail for your work and which are informational. The floor for anything entering a living system is identity plus purity plus endotoxin, and no price advantage justifies moving below it.
Peptide certificate of analysis requirements: what the document must contain
A defensible certificate is a batch-specific record, not a marketing document. It should carry the lot number printed on the vial, the methods that generated each result, the actual measured values, and the identity of the testing laboratory. The table below maps each attribute to what it proves and what its absence signals.
| Attribute | Peptide Synthesis Dab tsi nws pov thawj | Txoj kev | Accept t Synthetic Peptides hreshold | Red flag |
|---|---|---|---|---|
| Appearance | Gross handling and lyophilization quality | Visual | Consistent, documented | Not recorded |
| Identity | The material is the intended molecule | MS, ESI or MALDI; observed vs theoretical mass | Within ±1 Da of theoretical | A calculated mass with no spectrum |
| Assay, of total mass | Peptide plus counterion plus water | HPLC | Reported as a number | Absent |
| Assay, anhydrous and counterion-free | Net active peptide | Calculation from the above | Reported as a number | Absent — makes net content unknowable |
| Kev huv si | Relative purity against peptide-related impurities | e, method and column disclosed | ≥98%; ≥99% for quantitative and in vivo work | A threshold statement such as “greater than 95%” |
| Related substances | Impurity profile | e, orthogonal confirmation | Teev tseg, unspecified, and total impurities reported | A single percentage with no breakdown |
| a | How much of the weighed mass is water | Karl Fischer | Reported, and low | Absent |
| Counterion identity and content | Salt form and its contribution to mass | Ion chromatography or equivalent | Identity plus quantified content | Salt form not disclosed |
| Residual solvents | Process residue control | Per ICH Q3C | Reported against limits | Not tested |
| Elemental impurities | Catalyst thiab reagent nqa mus | Raws li ICH Q3D | Yog muaj feem xyuam rau txoj kev | Tsis tau ntsuas |
| Bacterial endotoxins | Pyrogen load | LAL lossis rFC, Raws li USP ⟨85⟩ | Tau tshaj tawm hauv EU/mg nrog txoj kev | Tsis muaj txiaj ntsig rau cov khoom siv txhaj tshuaj |
| Kev huv si thiab bioburden | Microbial contamination | Raws li USP ⟨71⟩ yog tsim nyog | Txuas nrog ib txoj kev teev npe | Ib qho lus qhia ntawm tus neeg muab khoom es tsis yog kev kuaj |
Pawg no tsis yog kev xaiv tsis muaj laj thawj. Nws qhia txog qhov uas cov qauv sau ntawv rau cov tshuaj peptide synthetic piav qhia, Thiab qhov kev sim pib ntawm molecular hnyav thiab huv mus txog cov ntsiab lus, dej, Salt, x, Thiab pH. Yog koj xav tau ib daim duab tseeb ntawm cov teb chaws ntawd zoo li cas ua ib lub panel ua haujlwm, Cov khoom kuaj uas peptide CoA tsim los ntawm Qhia lawv raws li kev txiav txim.
Identity: mass spectrometry is the floor, not the ceiling
K. e, v, sequence-level confirmation comes from LC-MS/MS rather than a single intact-mass measurement.
l 1 Da. e. A 1 e. s, and it will not catch a modification placed on the wrong residue. p 2,000 Da, a, u, PEGylation, lipidation, b, the 2026 FDA draft guidance on analytical procedures for synthetic peptides points to high-resolution mass spectrometry with fragmentation analysis for sequence confirmation. That is a different level of evidence than an intact mass, and it is the level a modified GLP-1 analogue actually requires.
HPLC purity vs peptide content: the quality metric that misleads
These are two different measurements, and conflating them is the most consequential misreading in peptide sourcing.
HPLC purity is a ratio. It compares the target peptide peak against peptide-related impurities — truncated sequences, deletion products, oxidized species — and reports a percentage of the total. It says nothing about what else is in the vial.
N. e, t, and water. p. Raws li e p (2025) t, i, d.
e. Two vials both reported at 99% c. o, n. t, once calculated anhydrous and counterion-free — and why a certificate showing only purity has not actually told you what you bought.
Counterion and TFA load: the quality attribute most certificates omit
Here is the gap that matters most, and it is the reason this section exists.
Trifluoroacetic acid is the standard ion-pairing agent in reversed-phase purification, and it persists bound to the basic residues of the peptide. Then something counterintuitive happens: TFA does not appear as an impurity peak in routine UV HPLC purity analysis. The purity percentage is calculated against peptide-related fragments. The counterion is invisible to it.
So a peptide can be reported at 99% purity and still carry a counterion load that changes your results. The reported effects are not subtle.
Residual TFA reduces net peptide content, because it occupies mass that is not peptide. S 0.1% a 214 thiab 220 nm, with u m. N, w s, which can make a sample look less pure or less concentrated than it is. t, x. o, t, i.
o n: i, z. o, j. Where TFA load is a problem, n; o ,.
⚠️ Warning: A 99% HPLC purity figure tells you nothing about TFA load. If the certificate does not report counterion identity and content, you cannot calculate net peptide mass — and if a cell-based assay gives an unexpected result, a TFA-only control at equivalent exposure is the fastest way to find out whether the counterion, n, produced the signal.
Impurity profile: a percentage is not a profile
A purity number is a summary. What you need is a profile.
s, expect specified identified impurities, specified unidentified impurities, unspecified impurities, and a total. USP ⟨1503⟩ on the quality attributes of synthetic peptide drug substances treats peptide content, assay, related substances, and the accompanying physical tests as the attribute set a specification should be built around, and each specified impurity should carry its own limit with demonstrated resolution from the main peak at the limit concentration.
Qhov chaw tswj hwm tau tsiv mus 2026. A 2026 kev tshuaj xyuas hauv Journal of Pharmaceutical Innovation hais txog kev tswj hwm thiab kev tshuaj xyuas txog zoo ntawm peptide hais tias cov impurities uas muaj feem xyuam rau peptide uas pom ntawm 0.10% lossis ntau dua ntawm cov tshuaj yuav tsum tau txheeb xyuas, nrog kev piav qhia qauv uas xav tau rau cov impurities ntawm qib ntawd hauv peptides hauv 20 amino acids. EMA txoj cai qhia txog kev tsim thiab kev tsim cov peptides synthetic, effective from 1 June 2026, sets reporting thresholds 0.1%, identification thresholds 0.5%, thiab qualification thresholds 1.0%, txuas nrog European Pharmacopoeia general monograph es tsis yog small-molecule ICH Q3A framework. Nws tseem xav kom muaj kev txheeb xyuas cov impurities uas muaj feem xyuam rau peptide siv tsawg kawg ob txoj kev orthogonal.
Tej zaum koj yuav tsis xa IND rau lub quarter no. Vim li cas cov threshold no tseem ceeb yog vim lawv qhia tias kev txheeb xyuas impurity muaj peev xwm zoo li cas, thiab lawv yog yam uas pab pawg tshuaj ntsuam ntawm tus neeg muab khoom yuav lees paub tias yog tus qauv. Daim ntawv pov thawj qhia txog cov sequences uas raug txiav, oxidized species, deamidated forms, epimers, thiab aggregation-related species ua qhov txawv, cov categories muaj lej qhia tias tau ua haujlwm tshuaj ntsuam. Ib daim ntawv pov thawj qhia ib tus lej thiab tsis muaj lwm yam qhia tias tsis yog.
Orthogonal verification: why one method is never enough
Reversed-phase HPLC cais los ntawm hydrophobicity. Cov impurities uas muaj hydrophobicity zoo sib xws co-elute nrog lub ntsiab peak thiab ploj mus rau hauv tus lej purity. Qhov no tsis yog kev xav xwb — nws yog qhov laj thawj uas ib qho qauv tuaj yeem zoo li huv ntawm ib txoj kev tab sis tsis ua tiav rau lwm txoj kev. s 2026 Kev cia siab ntawm tsawg kawg ob txoj kev orthogonal rau kev txheeb xyuas impurity muaj vim ib txoj kev muaj qhov tsis pom thiab tsis muaj txoj kev qhia nws.
Orthogonality hauv kev ua haujlwm rau peptide zoo li no: Ib txoj kev hloov theem thib ob siv ib qho tshuaj ntsuam theem ruaj khov txawv, Yog li co-elution qauv hloov; LC-MS lossis LC-MS/MS rau kev lees paub raws li qhov hnyav ntawm qhov peaks tiag tiag; Kev tshuaj xyuas amino acid rau kev sib xyaw; size-exclusion chromatography ua ke nrog multi-angle light scattering thaum aggregation yog ib qho teeb meem; capillary electrophoresis rau cov qauv them nqi. Peptide kev kuaj thiab tshuaj xyuas piav txog yuav ua li cas cov txheej txheem no sib xyaw ua ke hauv ib txoj kev txheeb xyuas tag nrho.
Lo lus nug tshuaj xyuas ua raws li qhov no: txoj kev thib ob uas siv, thiab nws qhia dab tsi?
Endotoxin, x, and bioburden
Kev kuaj endotoxin tsis yog xaiv tau rau txhua yam uas yuav kov cov hlwb, organoids, lossis ib qho qauv tsiaj. Nws ntsuas los ntawm Limulus amebocyte lysate assay piav qhia hauv USP ⟨85⟩, kev kuaj endotoxins ntawm kab mob, lossis los ntawm recombinant reagents hauv tshooj USP tshiab, nrog cov txiaj ntsig qhia hauv endotoxin units ib milligram lossis ib vial. Qhov kev piav qhia yog koj li, tsis yog tus neeg muab khoom: teeb qhov txwv raws li koj qhov kev ntsuas thiab txoj kev xav tau. FDA's kev qhia txog kev qhia txog bacterial endotoxins tham txog kev txwv raws txoj kev siv, thiab cov no yog cov ntsiab lus siv rau kev teeb tsa qhov siab tshaj plaws es tsis txhob lees txais tus naj npawb twg tshwm sim.
Kev huv si yog ib qho kev sim sib txawv nrog ib qho kev txwv tshwj xeeb. USP ⟨71⟩ npog kev tsis muaj kab mob; USP ⟨85⟩ npog endotoxin. Lawv feem ntau raug sib xyaw hauv cov khoom muab khoom thiab lawv teb cov lus nug sib txawv. Kev kuaj tsis muaj kab mob yog qhov tseem ceeb tshaj plaws rau hauv lub cev, txhaj tshuaj, lossis cov khoom siv tswj hwm thiab tsis cuam tshuam rau ib qho peptide tshawb fawb uas tau lyophilized tas li uas yuav rov tsim dua rau kev siv hauv vitro — tab sis thaum tus neeg muab khoom hais txog nws, qhov kev thov yuav tsum hu txoj kev es tsis yog hais txog ib qho xwm txheej.
C. o v hauv kwv yees 18% n, t. a, u.
What GLP-1 chemistry does to the quality problem
b, thiab nws tsim nyog piav meej vim li cas. n, t.
Site-specific lipidation and same-mass isomers
a, thiab tirzepatide nyob ntawm kev teeb tsa lipid-linker kom raug. Kev txuas ntawm lysine tsis raug, lossis ntawm N-terminus, tuaj yeem tsim ib qho isomer chaw nrog tib qho hnyav tsis puas. Kev lees paub qhov hnyav tag nrho yuav tsis cais lawv. Qhov txiaj ntsig tshuaj yog ib qho molecule nrog tib qho qauv, tib qho hnyav molecular ntawm daim ntawv pov thawj, thiab tej zaum yuav muaj kev sib txuas thiab kev ua haujlwm muaj zog txawv.
Semaglutide side chains kuj nqa lawv tus kheej impurity qeb — mono-AEEA, tri-AEEA, and β-alanine species — which have to be controlled during side-chain synthesis to protect the final material.
The implication is direct: for a lipidated GLP-1 peptide, intact-mass identity is necessary but not sufficient. Proving the modification sits where it should requires fragmentation analysis or peptide mapping, not a mass number. Peptide Production
Non-standard residues, deletions, and truncations
Aib — 2-aminoisobutyric acid — is a sterically hindered residue that couples more slowly than canonical amino acids because of its gem-dimethyl alpha-carbon. Protocols for it typically need extended reaction times or double coupling to reach complete incorporation, and incomplete incorporation produces des-Aib and other short-sequence variants. Because Aib is not one of the twenty standard residues, routine amino acid analysis does not track it reliably; MS and peptide mapping do.
Then there is the accumulation problem. Tirzepatide is assembled over roughly 39 cycles, thiab even small per-cycle inefficiency compounds across that many steps into a family of backbone deletions and truncations. Aib-position diastereomers at defined positions are an expected impurity class rather than a surprise. Diketopiperazine formation is a specific risk for sequences with an unprotected N-terminus.
| Attribute | Txoj kev | Accept | Red flag |
|---|---|---|---|
| Lipidation tshwj xeeb rau qhov chaw | Fragmentation MS lossis peptide mapping | Kev hloov kho ntawm qhov seem uas xav tau | Tsis muaj qhov hnyav tag nrho |
| Aib thiab cov seem tsis yog qauv | MS, peptide mapping | Kev koom ua ke tag nrho, stereochemistry raug | Kev tshuaj xyuas amino acid tsuas yog siv xwb |
| Kev tshem tawm thiab txiav txim series | RP-HPLC nrog kev lees paub orthogonal | Kev txwv ib leeg ntxiv tag nrho | Tsis tau tshaj tawm ua pawg |
| Diastereomers | Chiral lossis kev cais siab daws teeb meem thaum tsim nyog | Txwv tshwj xeeb | Tsis tau ntsuas |
| Diketopiperazine | e | Tsawg dua qhov txwv | Tsis tau saib xyuas |
Aggregation and the purification bottleneck
Lipidated peptides yog hydrophobic, thiab hydrophobic peptides muaj kev sib txuas tus kheej. Kev sib txuas tus kheej tshwm sim thaum synthesis, kev txiav, concentration, kev khaws cia, thiab kev ntxuav. Nws ua rau kev tsim khoom pom tsis tau, nws ua rau chromatography tsis yooj yim kwv yees, thiab nws tuaj yeem nyob ntev ua hom molecular-weight uas txoj kev purity hloov theem yuav tsis tshwm sim. Size-exclusion chromatography is the orthogonal method that catches it.
Purification is where this becomes expensive. As chain length and hydrophobicity rise, the target peptide and its nearest impurities acquire very similar reversed-phase behavior, so a single preparative HPLC step is frequently not enough. Long lipidated peptides often need multistep purification with orthogonal steps — ion exchange, SEC, precipitation, or nanofiltration. Tirzepatide’s commercial route illustrates the compounding effect: a hybrid solid-phase and liquid-phase strategy built from purified fragment intermediates, which multiplies the number of points at which consistency has to hold.
For a buyer, the takeaway is that a supplier capable of making a short linear peptide may genuinely be unable to deliver a consistent lipidated GLP-1 analogue, and the difference will not always be visible in a purity percentage.
Peptide raw material supplier qualification: the manufacturing evidence behind the certificate
A certificate of analysis is an output. The discipline that produces it is a process, and the process is verifiable — through records a qualified supplier already maintains. This is the part of supplier qualification that a certification badge does not cover.
In-process control and batch records
Expect defined control points across synthesis, purification, filtration, drying, and packaging, each with stated acceptance criteria, recorded results, and a reviewer signature. Expect a master batch record defining the process and a fully executed batch record for the specific lot you are buying, showing materials used, equipment identifiers, operator signatures, timestamps, yields, cov txiaj ntsig hauv txheej txheem, txhua yam kev kho dua tshiab lossis kev ua dua tshiab, thiab kev tso tawm QA kawg. Cov ntaub ntawv yuav tsum tau sau thaum ua haujlwm, tsis txhob rov tsim dua tom qab — GMP qauv rau cov tshuaj muaj zog yuav tsum tau sau cov haujlwm zoo tib lub sijhawm thiab tshawb xyuas cov kev txawv tseem ceeb nrog cov lus xaus sau tseg.
Deviation, CAPA, and change control
Thov daim ntawv sau kev hloov, daim ntawv sau kev kho thiab kev tiv thaiv, thiab kev tshuaj xyuas kev ua tau zoo tshiab. Kev hloov uas kaw tsis muaj qhov laj thawj tseem ceeb thiab kev tshuaj xyuas kev ua tau zoo uas tau txheeb xyuas tsis yog kev hloov kaw; nws yog kev pheej hmoo uas tsis tau tshuaj xyuas. Nug tias yuav ua li cas rau cov txiaj ntsig tsis raws li kev qhia thiab kev contamination raug tswj, thiab nug tias muaj dab tsi tshwm sim thaum kawg tshwm sim.
Kev tswj kev hloov yog ib nrab ntxiv. ICH Q7 requires a formal system for evaluating changes that may affect production and control of an intermediate or API, including changes to raw materials, methods, cov cuab yeej, facilities, software, and specifications, with risk assessment and re-validation where warranted. What cGMP actually covers in peptide manufacturing extends to raw-material traceability, batch documentation, kev tswj kev hloov pauv, and the audit trail from starting material to finished vial. Y, o, g, you want to see the impact assessment and the comparability data — because that change is the mechanism by which last year’s good lots become this year’s marginal ones.
Equipment qualification and environmental control
t, i, a. s, operational, t, u, s, and cleaning or hold-time data. n.
e. e, g, differential pressure, temperature, m, cov ntaub ntawv ntxuav thiab tua kab mob, kev txwv ceeb toom thiab kev ua haujlwm, thiab kev tshuaj xyuas kev hloov pauv dhau sijhawm. Kev tshuaj xyuas kev hloov pauv yog qhov uas raug hla dhau. Ib qho kev suav particle dhau mus yog ib daim duab snapshot; daim duab qhia kev hloov pauv nrog kev tshawb xyuas yog pov thawj ntawm ib qho chaw tswj tau. Kev tsim khoom hauv ib puag ncig tswj tau piav qhia txog kev faib thaj chaw thiab kev saib xyuas thoob plaws hauv ib lub chaw peptide sib xyaw, uas yog ib qho kev siv tau zoo rau seb cov ntaub ntawv yuav tsum zoo li cas ua ntej koj txais ib qho kev thov ib puag ncig.
Proving the mg-to-kg bridge
Kev pheej hmoo nce qib raug tsawg nqi vim nws ua tsis tiav yam tsis muaj suab. Ib txheej txheem uas tau lees paub ntawm 50 mg tsis yog pov thawj txog ib qho 500 g run. Dab tsi hloov tsis yog daim ntawv qhia tab sis yog cov ntsiab lus tseem ceeb ntawm txheej txheem, kev sib xyaw thiab kev hloov pauv loj, kev thauj khoom ntxuav, thiab lub voj voog lyophilization.
Ask for a process validation or scale-up report showing comparability across scales: impurity profile, yield, purity, and critical process parameters at each scale, with the analytical data to support the comparison. Where synthesis relies on fragment intermediates, as most long GLP-1 molecules do, xav tau cov ntaub ntawv sib piv ntawm qib fragment thiab. Txoj kev zoo tshaj rau cov sequences uas nyuaj rau synthesize muab ib qho kev xav txog seb kev tsim txoj kev thiab kev kho kom huv zoo li cas thaum ib sequence tsis ua raws li cov xwm txheej txheem, uas yog lo lus nug tiag tiag tom qab seb tus neeg muab khoom puas tuaj yeem tuav ib qho specification thaum volume nce.
How to verify a supplier before you commit
Txhua yam saum toj no ua ib qho kev thov tshuaj xyuas. Tso tawm ua ntej koj tso qhov kev txiav txim, tsis yog tom qab kev tshawb fawb poob.
Documents to request, and what a refusal tells you
Thov daim ntawv pov thawj lot-matched ua ntej yuav. Xyuas kom tus lej lot ntawm daim ntawv pov thawj phim tus lej lot ntawm lub raj thiab cov ntaub ntawv xa khoom. Xyuas kom daim ntawv pov thawj npe lub chaw kuaj nrog cov ntaub ntawv tiv tauj uas paub tau, thiab kom muaj peev xwm txheeb xyuas tau daim ntawv pov thawj. Thov cov ntaub ntawv raw tom qab cov lus piav qhia: chromatogram nrog retention time thiab peak-area data, mass spectrum nrog mass pom thiab qhov hnyav theoretical.
Sijhawm yog kev kuaj mob. Tus neeg muab khoom uas tsim daim ntawv pov thawj uas phim rau lot-matched hauv ib hnub lossis ob hnub muaj nws rau pawg ntawd. Tus neeg muag khoom uas xav tau ib lub lis piam nrhiav tau feem ntau tsis muaj daim ntawv pov thawj rau pawg ntawd, thiab yam tuaj txog yog daim qauv.
The red-flag list
| Signal | Nws qhia li cas | Yuav nug dab tsi |
|---|---|---|
| Tsis muaj daim ntawv pov thawj ua ntej yuav | Daim ntawv no tsim tom qab muag | Xa daim ntawv pov thawj tshwj xeeb rau pawg uas koj yuav xa. |
| Daim ntawv pov thawj dav dav lossis qauv | Tsis muaj kev kuaj tshwj xeeb rau pawg khoom | Daim ntawv pov thawj no yog pawg twg?' |
| Qhia txog kev huv ntawm qhov txwv (ntau tshaj 95%) | Tsis muaj tus nqi ntsuas | Qhov ntsuas huv yog dab tsi, thiab txoj kev yog dab tsi?' |
| Tsis muaj MS ntaub ntawv, Tsis muaj tsuas yog HPLC | Tsis tau lees paub tus kheej | Xa spectrum nrog qhov hnyav pom thiab kev xav. |
| Salt form not disclosed | Qhov hnyav peptide net tsis paub | “What is the counterion, and what is its content?' |
| Certificate older than twelve months for current inventory | Stale data applied to new stock | “What is the test date for this lot?' |
| No named testing laboratory | Results may be in-house and unverifiable | “Which laboratory performed the testing?' |
| Price far below market | Counterfeit, underdosed, or substituted material | “What explains the differential?' |
| Evasiveness on batch records or deviations | Records may not exist | “Send the executed batch record and deviation log.” |
| In-house testing offered as the only option | No independent verification path | “Will you support third-party retesting?' |
Two of these deserve emphasis because they are the ones buyers most often talk themselves past. A 2022 Analytical Chemistry study of commercially available peptides found that 23% tsis tau ua raws li lawv cov kev cai huv si, thiab tus nqi yog ib qho cim zoo tib txoj kev: kev sib txawv deb heev qis dua nruab nrab rau tib yam tshuaj tsis yog kev ua haujlwm zoo, nws yog ib yam khoom txawv. Thiab qhov tsis muaj ntsev tsis yog ib qho ntawv sau xwb — yog tsis muaj nws, tus naj npawb koj ntsuas tej zaum yuav tsis yog qhov ntau ntawm peptide uas koj xav tias koj muaj.
Third-party retesting and lot statistics
Kev kuaj dua tshiab ywj pheej yog koj qhov kev kuaj xyuas tsuas yog ib qho uas tsis nyob ntawm cov lus ntawm tus neeg muab khoom, thiab nws tsim nyog tus nqi rau txhua yam khoom uas nkag mus rau hauv lub cev muaj sia. Khiav nws thaum tau txais, thiab saib tus neeg muab khoom txoj kev npaj siab txhawb nqa nws raws li ib feem ntawm kev txiav txim siab tsim nyog es tsis yog tom qab nws. FDA kev tshuaj xyuas ntawm cov chaw peptide tau hais ntau zaus txog cov ntaub ntawv batch ploj thiab tsis muaj zog txaus, purity, thiab kev kuaj sterility, which is the gap independent retesting is designed to close.
The strongest evidence does not come from any single lot, though. Ask for historical lot statistics: mean, standard deviation, and percent relative standard deviation for purity, tus kheej, and key impurities across multiple lots. One passing certificate proves one lot passed. A tight distribution across ten lots is evidence of a controlled process — and it is the difference between a supplier who got it right once and a supplier who gets it right.
Pro Tip: The lot-statistics request is the highest-signal question in the whole audit. Suppliers who track percent RSD across lots will answer immediately, because they already have the data. Suppliers who do not will answer with a single certificate. Either response tells you something useful, thiab koj tau siv ib email thiaj tau txais nws.
Cov lus nug uas tshwm sim ntau zaus
Kuv yuav paub li cas tias daim ntawv pov thawj peptide puas yog tseeb?
Xyuas peb yam uas nyuaj rau dag ua ke: tus lej pawg phim lub raj thiab cov ntaub ntawv xa khoom; daim ntawv pov thawj qhia npe ib lub chaw kuaj uas koj tuaj yeem txheeb xyuas tus kheej thiab pov thawj; thiab nws muaj cov ntaub ntawv tshuaj ntsuam raw — ib qho chromatogram nrog lub sijhawm khaws cia thiab cov ntaub ntawv peak-area, thiab ib qho mass spectrum nrog kev pom piv rau qhov hnyav theoretical. Ib daim ntawv pov thawj uas tsis muaj ib qho ntawm peb yog ib qho kev thov tsis yog ib qho ntaub ntawv. Ib daim ntawv pov thawj uas qhia txog qhov txwv es tsis yog tus nqi ntsuas yog qhov qhia meej tshaj plaws.
GLP-1 cov ntaub ntawv tshawb fawb yuav tsum muaj kev huv npaum li cas?
Rau kev tshawb nrhiav ib txwm, HPLC huv ntawm lossis siab dua 95% nrog MS cim yog qhov tsawg kawg nkaus. Rau kev ntsuas tshuaj lom neeg thiab txhua yam piv txwv, 98% lossis siab dua nrog daim ntawv pov thawj tshwj xeeb yog tus qauv ua haujlwm, thiab 99% yog qhov kev cia siab ntau ntxiv. Rau kev ua haujlwm hauv lub cev, 99% ntxiv rau kev kuaj endotoxin, thiab kev huv si thaum txoj kev xav tau. Kev huv xwb tsis txaus — a 99% tus naj npawb huv nrog ib qho counterion load uas tsis tau tshaj tawm tsis qhia koj tias pes tsawg peptide nyob hauv lub raj.
HPLC purity puas yog tib yam li peptide ntsiab lus?
PM, thiab qhov txawv yog ntsuas tau. HPLC purity yog qhov piv ntawm peptide hom phiaj rau cov impurities uas cuam tshuam nrog peptide. Peptide content is the mass of active peptide, excluding counterion and water. A lyophilized powder contains all three, so two vials at identical purity can contain different amounts of peptide. This is why a certificate should report assay both of total mass and calculated anhydrous and counterion-free, and why buying on gross weight without that data introduces an unquantified error.
Why does TFA matter in peptide material?
TFA is the ion-pairing agent used in reversed-phase purification, and it remains bound to the peptide’s basic residues. It is not counted as a peptide-related impurity in routine HPLC purity analysis, so it hides behind a high purity number while reducing net peptide content. S 0.1% by weight it also skews UV quantification, suppresses ionization in mass spectrometry, alters CD and IR spectra, and can bias cell-based assays in either direction. Where it matters, quantify it — ion chromatography and ¹⁹F NMR are the practical methods — and consider ion exchange to acetate or HCl.
r
Take one active supplier and issue the audit request this week: lot-matched certificate with method disclosure, raw chromatogram and spectrum, counterion identity and content, water content, endotoxin in EU/mg, executed batch record, deviation and CAPA log, change-control log, equipment qualification records, environmental monitoring trends, and lot statistics with percent RSD. Then apply a simple gate: any attribute that is a hard gate for your tier and cannot be produced is unresolved risk, not a minor gap. Unresolved risk on material entering a living system should end the evaluation.
The market will keep producing GLP-1 peptides. The qualification question — whether the supplier can prove what they shipped — is the one that still separates a usable supply chain from a crowded one.
This article covers material quality and analytical characterization for research and development buyers. It is not medical advice, not prescribing guidance, and not a substitute for your own quality unit’s specification review or regulatory assessment.
